<DOC>
	<DOC>NCT00362609</DOC>
	<brief_summary>The purpose of this study is to determine whether or not consistent drug levels can be achieved in infants with presumed Gastroesophageal Reflux Disease.</brief_summary>
	<brief_title>Study Evaluating Pantoprazole in Neonates and Preterm Infants With GERD</brief_title>
	<detailed_description />
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Pantoprazole</mesh_term>
	<criteria>Hospitalized patients Presumed diagnosis of GERD Term or postterm infants within the neonatal period less than 28 days or preterm infants with a corrected gestational age of less than 44 weeks cardiovascular instability clinically significant laboratory abnormalities use of warfarin, carbamazepine, phenytoin, or rifampin</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>28 Days</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Safety</keyword>
</DOC>